Overview
The study is tissue-based, retrospective and prospective, single-centre, non-sponsored.
Primary objective: To examine patient and organ survival and eGFR variation in kidney transplant patients diagnosed histologically with cAMR.
Description
At the kidney transplant follow-up clinic of the UO Nephrology, Dialysis and Transplantation Unit of the IRCCS AOUBO Policlinico di Sant'Orsola, directed by Prof. G. La Manna, all patients with a diagnosis of cAMR made since 01/01/2018 and patients with a new diagnosis of cAMR made after the approval of this protocol by the Ethics Committee will be enrolled.
The study will last 5 years and 6 months.
Eligibility
Inclusion Criteria:
- Age ≥18 years
- Kidney transplant recipients
- eGFR>15 ml/min/1.73 sq m at the time of diagnosis of cAMR
- cAMR diagnosis defined on the basis of the 2018 Banff Classification (17), made after 1/1/2018.
- Obtaining Informed Consent to Participation.
Exclusion Criteria:
- Combined transplant patients (heart-kidney, liver-kidney or kidney-pancreas)
- Histological evidence of concomitant disease (e.g. recurrence of original nephropathy or diagnosis of 'de novo' nephropathy, acute cellular rejection, polyomavirus BK nephropathy, other)